Therapeutics for NAFLD and NASH This is the first time as far as I can say Tesamorelin has been mentioned in a recent article as a therapeutic drug for NAFLD/NASH.
"Growth hormone-releasing hormone (GHRH) is an endocrine hormone produced in the hypothalamus and works on its receptor (GHRH-R) in the anterior pituitary to stimulate the release of growth hormone (GH). GH subsequently can engage hepatocytes to produce insulin-like growth factor-1 (IGF-1) and induce lipolysis in adipocytes via promotion of hormone-sensitive lipase. The GHRH analog tesamorelin, which is modified with a hexanoyl moiety at the N-terminus to improve proteolytic stability, has shown benefits in HIV patients with lipodystrophy and GH deficiency to reduce circulating triglycerides and visceral adipose fat [106] and decrease in serum levels of ALT [107]. In HIV patients with NAFLD, tesamorelin (2 mg daily) caused a greater reduction in relative hepatic fat fraction (37%) relative to placebo (therapy group decreased by 32%, whereas a placebo group gained 5%) [108]. As expected, IGF-1 levels increased and visceral adipose tissue decreased, but circulating triglycerides trended to increase after 12 months of treatment. An analysis of biopsied livers demonstrated that tesamorelin increased transcriptional markers of oxidative phosphorylation and decreased gene sets linked to inflammation [109]. Whether these benefits on hepatic fat content translate to non-HIV patients remains to be proven, but recent clinical results with GH in obese NAFL patients [110] lend credence to targeting this biological pathway for NASH benefits. The recently announced phase 3 trial of tesamorelin in general NASH patients will hopefully provide definitive proof."
https://www.sciencedirect.com/science/article/pii/S2212877820302271